» Articles » PMID: 21464199

Cyclopentenyl Cytosine Induces Senescence in Breast Cancer Cells Through the Nucleolar Stress Response and Activation of P53

Overview
Journal Mol Pharmacol
Date 2011 Apr 6
PMID 21464199
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The induction of senescence has emerged as a potentially important contributor to the effects of chemotherapeutic agents against tumors. We have demonstrated that depletion of CTP induced by cyclopentenyl cytosine (CPEC; NSC 375575), a specific inhibitor of the enzyme CTP synthetase, induces irreversible growth arrest and senescence characterized by altered morphology and expression of senescence-associated β-galactosidase activity in MCF-7 breast cancer cells expressing wild-type p53. In contrast, differentiation in the absence of senescence resulted from CPEC treatment in MDA-MB-231 breast cancer cells that express a mutated p53. Both senescence of MCF-7 cells and differentiation of MDA-MB-231 cells were prevented by repletion of CTP through the cytidine salvage pathway. Senescence in MCF-7 cells was associated with a G(2)- and S-phase arrest, whereas differentiation in MDA-MB-231 cells was associated with arrest in G(1) phase at 5 days. Mechanistic studies revealed that CTP depletion induced a rapid translocation of nucleolar proteins, including nucleostemin and nucleolin into the nucleoplasm. This nucleolar stress response resulted in a sustained elevation of p53 and the p53 target genes, p21 and Mdm2, in cells with wild-type p53. Furthermore, short interfering RNA-induced knockdown of p53 in MCF-7 cells treated with CPEC prevented cellular senescence and increased apoptotic cell death. We conclude that CTP depletion and the resulting nucleolar stress response results in a senescence-like growth arrest through activation of p53, whereas cells with mutated p53 undergo differentiation or apoptotic cell death.

Citing Articles

Quadra-Stable Dynamics of p53 and PTEN in the DNA Damage Response.

Gupta S, Panda P, Silveira D, Ahuja R, Hashimoto R Cells. 2023; 12(7).

PMID: 37048159 PMC: 10093226. DOI: 10.3390/cells12071085.


In silico recognition of a prognostic signature in basal-like breast cancer patients.

Conte F, Sibilio P, Grimaldi A, Salvatore M, Paci P, Incoronato M PLoS One. 2022; 17(2):e0264024.

PMID: 35167614 PMC: 8846521. DOI: 10.1371/journal.pone.0264024.


BMH-21 inhibits viability and induces apoptosis by p53-dependent nucleolar stress responses in SKOV3 ovarian cancer cells.

Fu X, Xu L, Qi L, Tian H, Yi D, Yu Y Oncol Rep. 2017; 38(2):859-865.

PMID: 28656213 PMC: 5561869. DOI: 10.3892/or.2017.5750.


Small molecule compounds that induce cellular senescence.

Petrova N, Velichko A, Razin S, Kantidze O Aging Cell. 2016; 15(6):999-1017.

PMID: 27628712 PMC: 6398529. DOI: 10.1111/acel.12518.


Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.

Liang S, Peng X, Li X, Yang P, Xie L, Li Y Oncotarget. 2014; 6(2):1020-30.

PMID: 25544759 PMC: 4359214. DOI: 10.18632/oncotarget.2741.


References
1.
Ryden M, Dicker A, Gotherstrom C, Astrom G, Tammik C, Arner P . Functional characterization of human mesenchymal stem cell-derived adipocytes. Biochem Biophys Res Commun. 2003; 311(2):391-7. DOI: 10.1016/j.bbrc.2003.10.010. View

2.
Momand J, Zambetti G, Olson D, George D, Levine A . The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992; 69(7):1237-45. DOI: 10.1016/0092-8674(92)90644-r. View

3.
Politi P, Xie F, Dahut W, Ford Jr H, Kelley J, Bastian A . Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemother Pharmacol. 1995; 36(6):513-23. DOI: 10.1007/BF00685802. View

4.
Bothner B, Lewis W, DiGiammarino E, Weber J, Bothner S, Kriwacki R . Defining the molecular basis of Arf and Hdm2 interactions. J Mol Biol. 2001; 314(2):263-77. DOI: 10.1006/jmbi.2001.5110. View

5.
Te Poele R, Okorokov A, Jardine L, Cummings J, Joel S . DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002; 62(6):1876-83. View